Crinetics Pharmaceuticals

$14.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.29 (+9.87%) Today
$0.00 (0.00%) As of 5:00 PM EST after-hours

Why Robinhood?

You can buy or sell CRNX and other stocks, options, and ETFs commission-free!

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA. The listed name for CRNX is Crinetics Pharmaceuticals, Inc. Common Stock.

CEO
Scott R. Struthers
Employees
68
Headquarters
San Diego, California
Founded
2008
Market Cap
472.76M
Price-Earnings Ratio
Dividend Yield
Average Volume
190.81K
High Today
$14.54
Low Today
$13.10
Open Price
$13.10
Volume
71.48K
52 Week High
$26.67
52 Week Low
$10.63

Collections

CRNX Earnings

-$0.71
-$0.47
-$0.24
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, Pre-Market

You May Also Like